Lyell Immunopharma, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer treatment. The company aims to harness the power of the immune system to create effective therapies that can overcome the limitations of traditional cancer treatments. Lyell's proprietary technology platform is designed to enhance the persistence and functionality of T cells, enabling them to better target and eliminate cancer cells. With a strong emphasis on research and development, Lyell is committed to advancing its pipeline of therapies to improve patient outcomes in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

6 Patents

#137 in South San Francisco, CA

#10,583 in California

#45,030 in US

South San Francisco, CA, United States of America

Lyell Immunopharma, Inc.

Forward Citations = 0

23 inventors:

Marc J Lajoie (3 out of 18 patents)

Spencer Park (2 out of 2 patents)

Queenie Vong (2 out of 2 patents)

4. Blythe Sather (2 out of 2 patents)

5. Byoung Ryu (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lyell Immunopharma, Inc.. Retrieved from https://idiyas.com/company/lyell-immunopharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]